Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$629K Buy
9,338
+1,386
+17% +$92.3K 0.37% 82
2026
Q1
$499K Sell
7,952
-790
-9% -$55K 0.34% 88
2025
Q4
$580K Buy
8,742
+2
+0% +$129 0.4% 85
2025
Q3
$588K Buy
8,740
+136
+2% +$10.8K 0.43% 88
2025
Q2
$751K Sell
8,604
-398
-4% -$31.2K 0.58% 70
2025
Q1
$615K Buy
9,002
+488
+6% +$39.8K 0.55% 80
2024
Q4
$662K Buy
8,514
+2,179
+34% +$161K 0.57% 65
2024
Q3
$425K Buy
+6,335
New +$520K 0.37% 85

Other funds holding DXCM

Paladin Wealth's DXCM Position: Q2 2026 in Review

Paladin Wealth increased its DexCom (DXCM) stake by 17% in Q2 2026, buying an estimated $92.3K and bringing the position to 9,338 shares worth $629K. The position accounts for 0.37% of the portfolio, ranked #82.

Paladin Wealth first reported a position in DXCM in Q3 2024 and has held it in 8 quarters since. The position peaked at $751K in Q2 2025. 115 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Paladin Wealth held 9,338 shares of DexCom worth $629K as of Q2 2026.
  • Paladin Wealth bought 1,386 DexCom shares in Q2 2026, an estimated $92.3K.
  • DexCom made up 0.37% of Paladin Wealth's portfolio in Q2 2026, its #82 holding.
  • Paladin Wealth first reported a position in DexCom in Q3 2024 and has held it in 8 quarters since.
  • Paladin Wealth's DexCom position peaked at $751K in Q2 2025.
  • 115 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Paladin Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.